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Alterations in Skin and Stratified Epithelia
by Constitutively Activated PPARa
Qian Yang1, Atsushi Yamada1, Shioko Kimura1, Jeffrey M. Peters2 and Frank J. Gonzalez1
Peroxisome proliferator-activated receptor (PPAR)a is a pleiotropic regulator in many cell types and has recently
been implicated in skin homeostasis. To determine the role of PPARa in skin physiology, transgenic mice were
generated using the tetracycline Tet-off regulatory system to target constitutively activated PPARa to the
epidermis and other stratified epithelia by the bovine keratin K5 promoter. Expression of the transgene during
early development resulted in postnatal lethality within 2 days after birth. A thin epidermis, few hair follicles,
and abnormal development of the tongue were observed in neonatal transgenic mice. Early mortality was not
observed when transgenic PPARa expression was diminished by administration of doxycycline (dox) to the
mothers. The alterations noted in neonatal mice were not observed in adult mice upon re-expression of the
PPARa transgene by withdrawing dox. Attenuated hyperplasia of interfollicular epidermis after topical
application of the tumor promotor 12-O-tetradecanoyl-phorbol-13-acetate (TPA) was observed in adult mice
expressing the PPARa transgene. In addition, expression of the PPARa transgene in mammary gland during
pregnancy resulted in abnormal development of this organ and impaired lactation. Further investigations using
primary keratinocytes revealed that expression of the transgene in keratinocytes resulted in increased
differentiation and decreased proliferation, which may contribute to the observed phenotype in the transgenic
mice. Thus, these results indicate that PPARa plays an important role in the development of stratified epithelia
including skin, tongue, and mammary gland.
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INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily. Three isoforms
of PPARs (a, b/d, and g) have been identified in a variety of
species including frogs, rodents, and humans (Issemann and
Green, 1990; Sher et al., 1993; Amri et al., 1995; Greene
et al., 1995; Desvergne and Wahli, 1999). PPARs function as
transcription factors by the classic ligand-dependent nuclear
hormone receptor mechanism. Upon binding to their ligands,
PPARs undergo conformational changes that allow corepres-
sor release and coactivator recruitment, heterodimerization
with retinoid X receptor, and selective binding to direct
repeat 1 elements of the hexameric nucleotide sequence,
called the peroxisome proliferator-responsive elements, in
the promotors of target genes (Berger and Moller, 2002).
Consequently, the PPARs regulate the expression of target
genes involved in many cellular functions including fatty acid
storage, transport, and metabolism that lead to alterations in
cell proliferation, differentiation, and immune/inflammation
response (Kliewer et al., 1999; Kersten et al., 2000).
A diverse range of chemicals that include clinically
important drugs, industrial chemicals, and agrochemicals
are known exogenous PPARa ligands (Kersten and Wahli,
2000; Berger and Moller, 2002). Endogenous ligands for
PPARa include various fatty acids (Forman et al., 1996,
1997). Aside from the activation of genes important in fatty
acid catabolism, PPARa has been linked to the regulation of
genes important in cell growth and differentiation (Corton
et al., 2000; Kersten et al., 2000; Berger and Moller, 2002).
PPARs were initially investigated in skin because other
members of the nuclear receptor superfamily were found to
modulate cutaneous homeostasis (Winterfield et al., 2003).
Thyroid receptor, retinoic acid receptor, and vitamin D
receptor are well-known regulators of epidermal growth and
differentiation. In addition, mice lacking expression of
retinoid X receptor a, the major heterodimerization partner
for type 2 nuclear receptors, exhibit abnormal skin develop-
ment, epidermal hyperplasia, cutaneous inflammation, and
alopecia (Li et al., 2000, 2001). Indeed, the three different
PPAR isotypes have been identified in rodent and human
keratinocytes (Braissant et al., 1996; Braissant and Wahli,
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1998; Rivier et al., 1998; Michalik et al., 2002). A number of
PPARa ligands were shown to accelerate the morphological
and functional maturation of the epidermal barrier in fetal rat
skin both in vitro and in vivo (Hanley et al., 1997, 1998,
1999; Komuves et al., 1998). Topical application of PPARa
ligands to adult mouse skin also inhibits epidermal prolifera-
tion and induces keratinocyte differentiation (Komuves et al.,
2000a). Furthermore, these compounds restore epidermal
homeostasis in the murine models of hyperproliferative
epidermis (Komuves et al., 2000b).
Despite several lines of evidence suggesting that PPARa is
important in the skin, little is known about the molecular
mechanisms underlying its mode of action in this tissue. The
epidermis of PPARa-null mice has a thinner layer of stratum
granulosum, and the granular cells have fewer keratohyalin
granules (Komuves et al., 2000a). To investigate the role of
activated PPARa in the skin, the potent viral transcriptional
activator VP16 was fused to the mouse PPARa complemen-
tary deoxyribonucleic acid (cDNA) to create a transcription
factor that constitutively activates PPARa-responsive genes in
the absence of ligands. Transgenic mice were produced
whereby inducible expression of the VP16PPARa transgene
was targeted to the basal layer of the epidermis using the
tetracycline regulatory system under the control of a bovine
keratin K5 promotor (Diamond et al., 2000). The transgenic
mice presented dramatic phenotypes in the skin and other
ectodermally derived epithelia, identifying a role for PPARa
in the development and pathophysiology of these tissues.
RESULTS
Generation of K5/tTA TREVP16PPARa mice
A constitutively active PPARa was created by fusing the
potent viral transcriptional coactivator VP16 to the PPARa
cDNA (VP16PPARa) (Figure 1a). To compare the transcrip-
tional activity of VP16PPARa, the plasmid VP16PPARa and a
PPAR response reporter construct were transiently transfected
onto NIH-3T3 cell. As expected, Wy-14,643 markedly
activated transcription (2- to 3- fold) in the presence of
cotransfected PPARa in these cells (Figure 1b). Transcrip-
tional activation by VP16PPARa was dramatically greater
(over 100-fold) with both pVP16PPARa and pTRE-
VP16PPARa constructs, and doxycycline (dox) repressed this
latter activity. These results indicate that VP16PPARa is a
potent activator of positively regulated PPARa target genes.
Transgenic mice were generated with the VP16PPARa
cDNA driven by the tetracycline response element
(TREVP16PPARa) (Figure 1a). Subsequently, bitransgenic
(designated as VP16PPARa BT) mice were produced by
breeding the TREVP16PPARa transgenic mice with K5/
tetracycline-controlled transactivator (tTA) transgenic mice
expressing tTA under the control of the keratin 5 promotor
(Diamond et al., 2000) to reconstitute the tetracycline-
responsive regulatory system (Gossen and Bujard, 1992;
Gossen et al., 1995). In principle, in the absence of dox
(a tetracycline derivative), tTA binds to the TRE and directs
transcription of target gene, specifically in the skin and
several stratified epithelia (Diamond et al., 2000). Figure 1c
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Figure 1. Generation of transgenic mice and analysis of transgene expression. (a) Schematic representation of the 7-kb construct used for generating
tetracycline response element-VP16PPARa (TREVP16PPARa) transgenic mice. PminhCMV, minimal human cytomegalovirus promotor. (b) Transfection of
NIH-3T3 cells with indicated expression vectors using peroxisome proliferator-responsive element  3-TK-Luc reporter plasmid in the presence or absence of
PPARa ligand Wy-14,643 (100 mM) or dox (2 ng/ml). (1) VP16; (2) pSG5PPARa; (3) Wy-14,643þ pSG5PPARa; (4) pVP16PPARa; (5) pTREVP16PPARa; and (6)
Doxþ pTREVP16PPARa. Values with different letters are significantly different at Pp0.05 as determined by analysis of variance. (c) Northern blot analysis of
RNA extracted from neonatal mouse skin shows the expression of endogenous PPARa in each mouse and the expression of the VP16PPARa transgene only in
VP16PPARa BT mice in the absence of dox. Dox represses the expression of VP16PPARa. Note that endogenous PPARa is increased in VP16PPARa BT mice.
(d) Increased expression of PPARa in primary keratinocytes from neonatal VP16PPARa BT mice. The primary keratinocytes from neonatal VP16PPARa BT mice
treated with dox were cultured in low-calcium medium with dox for 2 days and then switched to medium with (þdox) or without (dox) for another 2 days.
Left: Northern blot analysis of RNA extracted from primary keratinocytes of neonatal VP16PPARa mice. Note that dox represses the expression of VP16PPARa
mRNA and the endogenous PPARa mRNA is not increased in primary keratinocytes. Right: Western blot analysis of protein extracted from primary keratinocytes
from neonatal VP16PPARa BT mice. Note that dox represses expression of the VP16PPARa protein.
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shows the expression of both endogenous PPARa and
transgenic VP16PPARa mRNA in neonatal skin samples.
The high-molecular-weight bands corresponding to the
endogenous mouse PPARa were detected in all samples,
whereas the mRNA corresponding to the transgenic
VP16PPARa only appeared in VP16PPARa BT mice in the
absence of dox. As expected, dox repressed the expression of
VP16PPARa in VP16PPARa BT mice as revealed by the
absence of VP16PPARamRNA in dox-treated VP16PPARa BT
mice. It should also be noted that the expression of
endogenous PPARa is highly induced by VP16PPARa in skin
samples (Figure 1c); however, this induction was not found in
primary keratinocytes isolated from neonatal VP16PPARa BT
mice (Figure 1d). Further, PPARa protein levels were also
induced by expression of the VP16PPARa transgene and
repressed by dox as revealed by Western blot analysis of
protein from primary VP16PPARa keratinocytes (Figure 1d).
Thus, by employing the tetracycline regulation system,
constitutive expression of VP16PPARa in mouse skin was
achieved.
VP16PPARa mRNA was specifically expressed in the skin,
tongue, and mammary gland tissue, but not in the liver and
stomach, which is consistent with the tissue specificity of the
K5 promotor (Diamond et al., 2000) (Figure 2a and b). In
addition, the expression of VP16PPARa was repressed by dox
treatment in the skin (Figure 1c) and tongue (Figure 2c). Thus,
tissue-specific expression of VP16PPARa is governed by the
specificity of the K5 promotor and tightly controlled by
tetracycline regulation system. It should also be noted that the
expression of endogenous PPARa is also modulated in
epithelial tissues where the K5 promoter is active (skin,
tongue, and mammary gland) (Figure 2a–c) and regulated by
dox treatment (Figures 1c and 2c) in the same manner as
VP16PPARa.
To gain further insights into the effects of the VP16PPARa
transgene on skin function, PPARa target gene expression was
examined in the neonatal skin of VP16PPARa BT mice in the
absence of dox. As expected, the expression of two PPARa
target genes, adipose differentiation-related protein and
fasting-induced adipose factor, which contain a peroxisome
proliferator-responsive element in their promotor regions and
play an important role in the uptake and accumulation of
lipid (Mandard et al., 2004; Targett-Adams et al., 2005), was
dramatically increased upon the expression of VP16PPARa
(Figure 2d). These results are consistent with a previous report
that activation of PPARa by its ligand stimulates the
expression of adipose differentiation-related protein and
fasting-induced adipose factor in keratinocytes (Schmuth
et al., 2004).
Postnatal death in VP16PPARa BT mice
The VP16PPARa BT mice were first generated by mating
transgenic TRE-VP16PPARa mice to transgenic K5/tTA mice.
The VP16PPARa BT pups appeared weaker, smaller, and no
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Figure 2. Northern blot analysis of PPARa expression in VP16PPARa BT mice. (a) mRNA analysis from skin, tongue (T), stomach (S), and liver (L). (b) mRNA
analysis from the mammary gland. (c) mRNA analysis from tongue in the absence or presence of dox. Note the expression of the VP16PPARa transgene only in
the skin, mammary gland, and tongue, but not in the liver and stomach. (d) Northern blot analysis of PPARa target genes adipose differentiation-related protein
(ADRP) and fasting-induced adipose factor (FIAF) and regulation by dox in neonatal VP16PPARa BT mouse skin. Bar graph shows the relative mRNA levels
regulated by VP16PPARa; the value for each group is the mean7standard error of mean; n¼3–4 mice per group (*Po0.05).
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milk was found in their stomachs as compared to their
littermates (wild type (Wt), TREVP16PPARa, and K5/tTA)
(Figure 3a). The average body weight of the VP16PPARa BT
pups (1.070.15 g; n¼ 10 pups) was only 60% of their
littermates (1.670.37 g; n¼ 25 pups). In contrast to their
littermates, VP16PPARa BT pups died within 2 days after
birth in the absence of dox (Figure 3b). However,
VP16PPARa BT pups from dox-fed dams appeared normal
at birth and no changes in body weight were observed as
compared to their littermates (Figure 3b). These observations
suggest that VP16PPARa BT mice could have suckling
problems. Histological examination of tongue in P1 pups
and their littermates revealed that VP16PPARa BT pups have
an abnormal tongue with fewer rudiments of filiform papillae
over the dorsal surface (Figure 3c). However, when dams
received dox in the diet, the abnormal phenotype was
rescued (Figure 3c). In addition, switching the diet adminis-
tered to dams from a dox diet to a normal chow diet after
birth did not result in any of the observed defects in the pups
up to the point of weaning. These results suggest that
activation of PPARa during early postnatal development can
negatively influence sucking by interfering with epithelial
differentiation of the tongue.
Impaired lactation in VP16PPARa BT mice
Further studies were performed to evaluate the potential
physiological defects underlying the impaired postnatal
development. To differentiate between effects due to altered
milk production and/or altered suckling, heterozygous
VP16PPARa BT mice were mated to produce pups. The
results showed that all pups (VP16PPARa BT and their
littermates Wt, TREVP16PPARa, and K5/tTA) produced by
heterozygous VP16PPARa BT dams were not obtaining milk
(Figure 4a) and died within 2 days of birth (Figure 4b).
However, when dams received dox from the diet, the
impaired phenotype was rescued (Figure 4b), demonstrating
that expression of the VP16PPARa transgene leads to a defect
in the mammary gland. To further differentiate between
effects due to altered milk production and/or suckling,
crossfostering studies were performed. Wt pups crossfostered
with VP16PPARa BT mice exhibited postnatal lethality within
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Figure 3. Postnatal lethality in VP16PPARa BT mice. (a) Photo of a
representative live VP16PPARa BT pup and a wild-type (Wt) littermate at
postnatal day 1 (PD1). Note that the VP16PPARa BT pup is smaller, and no
milk is observed in the stomach of VP16PPARa BT pup in contrast with the Wt
littermate. (b) Survival rate of VP16PPARa BT pups (BT) and their littermates
(Lit) at postnatal PD2. Data are representative for VP16PPARa BT (n¼ 11) and
littermates (n¼84) from n¼9 dams in the absence of dox, and for
VP16PPARa BT (n¼ 5) and littermates (n¼31) from n¼ 4 dams in the
presence of dox. Note VP16PPARa BT pups without dox were dead within 2
days after birth. (c) Photomicrograph of hematoxylin and eosin staining of the
dorsal surface of neonatal tongue. Note the few filiform papillae on the
tongue surface in VP16PPARa BT mice.
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Figure 4. Impaired lactation in VP16PPARa BT dams. (a) Photo of a
representative pup born from the VP16PPARa BT dams at PD1. Note the
absence of observable milk in the stomach. (b) Survival rate of VP16PPARa BT
pups and their littermates at PD2. Data are representative for VP16PPARa BT
(BT) (n¼16) and littermates (Lit) (n¼ 41) from n¼8 dams in the absence of
dox, and for VP16PPARa BT (n¼ 10) and littermates (n¼ 89) from n¼ 9 dams
in the presence of dox. Note that all pups from VP16PPARa dams without dox
were dead within 2 days after birth. (c) Crossfostering studies on survival rates
of VP16PPARa pups and their littermates at PD2. Data are representative for
non-VP16PPARa BT littermaters (Lit) (n¼ 20) fostered with wild-type (Wt)
dams (n¼3); VP16PPARa BT pups (BT) (n¼ 8) fostered with Wt dams (n¼ 3);
and Wt pups (n¼ 25) fostered with VP16PPARa BT dams (n¼3). Note that
both VP16PPARa BT pups fostered with Wt dams and Wt pups fostered with
VP16PPARa BT dams were dead within 2 days after birth. (d) Photomicro-
graph of whole-mount staining of mammary gland in Wt and the VP16PPARa
BT dams. Note the impaired development of lobuloalveolar unit in the
VP16PPARa BT dam (arrow).
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2 days. A similar lethality was observed in VP16PPARa BT
pups fostered with Wt dams (Figure 4c). Thus, these data
suggest that lactation could be impaired in the transgenic
dams. Consistent with this hypothesis, histological examina-
tion of mammary glands revealed that the VP16PPARa BT
dams failed to develop lobuloalveolus on postnatal day 1
during development of the mammary gland compared to
their littermates (Figure 4d). These findings show that
expression of the VP16PPARa transgene during pregnancy
might result in abnormal development of the myoepithelium
in the mammary gland that inhibits the ability to produce
milk. Combined, the abnormal phenotype found in postnatal
tongue and the defective phenotype in the mammary gland
indicate that the postnatal lethality was due to defects in both
the VP16PPARa BT dams and the pups.
Altered development of skin in VP16PPARa BT mice
A markedly thin interfollicular epidermis was observed in
VP16PPARa BT pups in the absence of dox compared with
their Wt littermates in the absence of dox (Figure 5a). This
was mainly due to the decreased granular cell layer
(Figure 5a). Further, these mice had few hair follicles, as
evidenced by the long distance between the follicles in the
absence of dox, and this phenotype was not observed in the
presence of dox (Figure 5a). At 6 weeks after switching to
non-dox chow, abnormal patchy hair development was
observed in the adult VP16PPARa BT mice. These transgenic
animals eventually developed a relatively thin hair coat
(Figure 5b). As expected, this phenotype was not observed in
the VP16PPARa BT mice maintained on dox chow. In
contrast to neonatal skin, no clear differences were observed
in the adult epidermis of VP16PPARa BT mice in the absence
of dox compared to their littermates (Figure 5c). However, the
number of suprabasal cell layers was dramatically increased
after topical 12-O-tetradecanoyl-phorbol-13-acetate (TPA)
treatment; the epidermis in the VP16PPARa BT mouse skin,
in the absence of dox, displayed reduced hyperplasia (Figure
5c). These results suggest a possible antiproliferative role for
PPARa signaling in the mouse epidermis.
Enhanced differentiation and decreased proliferation in primary
keratinocytes upon activation of the VP16PPARa transgene
To further analyze the epithelial phenotype of VP16PPARa
BT mice, primary keratinocytes were cultured from neonatal
VP16PPARa BT mice and their littermates in the absence of
dox. After plating the same number of cells, most keratino-
cytes from the VP16PPARa BT mice did not attach and grow
in the culture dish as compared to cells from their littermates
(Figure 6a). To overcome this defect in keratinocyte attach-
ment to culture dishes, keratinocytes from dox-treated
VP16PPARa BT mice were used in the following experiments.
In the presence of dox in the diet, keratinocytes isolated
from neonatal VP16PPARa BT mice exhibited the same
morphology compared with the cells from their littermates
(data not shown). However, 48 hours after withdrawal of dox
from the medium, keratinocytes, in the absence of dox,
exhibited a distinctly different morphology (Figure 6b), and
proliferated more slowly than Wt keratinocytes as shown
by comparison with cells cultured in the presence of dox
(Figure 6b). These observations are consistent with the
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Figure 5. Altered skin development in VP16PPARa BT mice. (a) Photomicrograph of hematoxylin and eosin staining of neonatal mouse skin in the presence or
absence of dox. Note fewer and underdeveloped hair follicles in VP16PPARa BT mice in the absence of dox (left panel); right panels are higher magnification of
epidermis, stratum corneum (blue), stratum granulosum (red), stratum spinosum (green), and stratum basale (yellow). Note the thin epidermis and granular cell
layer (right panel). (b) Photo of a representative adult VP16PPARa BT mice and their littermates; note the thin hair coat in VP16PPARa BT mice. (c) The
hyperplastic response of adult skin with or without topical TPA treatment as shown by hematoxylin and eosin staining. Note that no gross differences could be
observed in the VP16PPARa BT mice without treatment and the reduced hyperplasia of the epidermis in VP16PPARa BT mice.
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phenotype observed in the skin and further indicate that
differentiation and proliferation of kerationocytes are altered
by the expression of VP16PPARa.
To determine the extent of cell proliferation, the
incorporation of BrdU into keratinocytes was measured.
After 48 hours of dox withdrawal from the medium,
keratinocytes incorporated less BrdU, indicating less prolif-
eration as compared to keratinocytes in the presence of
dox (Figure 6c). In parallel, cell cycle analysis was also
performed. After withdrawal of dox from the medium, more
keratinocytes were in the G0/G1 phase, indicating cell
cycle arrest (Figure 6d). These data further demonstrate
that the expression of VP16PPARa decreases keratinocyte
proliferation.
To explore the molecular mechanism(s) underlying
VP16PPARa transgene regulation in keratinocytes, mRNA
encoding proteins associated with differentiation and pro-
liferation were examined in neonatal skin of VP16PPARa BT
mice, in the presence or absence of dox. Expression of the
keratinocyte differentiation marker mRNAs encoding involu-
crin and transglutaminase-1 were induced in the skin of
VP16PPARa BT mice, and repressed by dox treatment
(Figure 7a). This result is consistent with the observed
morphology of keratinocytes in primary culture and indicates
that activation of PPARa induces differentiation. Expression of
the known granular layer marker mRNAs encoding loricrin
and filaggrin were induced in the skin of VP16PPARa BT
mice, and repressed by dox treatment (Figure 7b). This result
is consistent with the altered granular layer in the epidermis
of transgenic mice (Figure 5a).
Expression of mRNAs encoding the cell cycle-regulating
protein cyclin D1 was reduced and p21 was induced in the
skin of VP16PPARa BT mice, and these effects were
diminished by dox treatment (Figure 7c). This result is
consistent with the observed phenotype of the skin and the
decreased keratinocyte proliferation in primary cultures, and
further indicates that the decreased proliferation of keratino-
cytes is due, at least in part, to altered cell cycle control in
VP16PPARa transgenic mice upon expression of the
VP16PPARa transgene.
+ Dox + Dox
Labelling: 8.5 ± 1.2
– Dox
Labelling: 2.4 ± 0.2*
104
103
102
101
100
FL
1-
H
104
103
102
101
100
FL
1-
H
0 200 400 600 800 1,000
FL2-A
0 200 400 600 800 1,000
FL2-A
0 200 400 600 800 1,000
FL2-A
0 200 400 600 800 1,000
FL2-A
100
80
60
40
20
0
Co
un
ts
Co
un
ts
G0/G1: 58.5 ± 3.2
– Dox
G0/G1: 72.4 ± 4.2*
0
30
60
90
120
150
Wt TREVP16PPAR + Dox − Dox
K5TA BT
500
400
300
200
100
0
0 1 2 3 4 5 6 7 8
Days
Ce
ll/w
e
ll 
(× 
1,
00
0) – Dox
+ Dox
M1 M2
M3 M3
M2M1
R3
R5
R4 R4
R5
R3
a
c d
b
*
*
*
*
Figure 6. Representative photomicrographs of primary keratinocytes from (a) wild-type (Wt), transgenic TREVP16PPARa, transgenic K5/tTA, or VP16PPARa
BT mice. Keratinocytes were obtained from PD1 pups and cultured for 1 day in the absence of dox; note that keratinocytes from VP16PPARa BT mice were
fewer. (b) (Upper) VP16PPARa BT mice in the presence of dox, cultured in low-calcium medium with dox for 2 days and then switched to medium with (þ dox)
or without (dox) for another 2 days. Note the morphology is changed with dox. (Down) Decreased cell proliferation upon activating VP16PPARa. Cell numbers
were quantified with a coulter counter over a 7-day culture period. (c) Proliferation of VP16PPARa BT keratinocytes in the presence or absence of dox.
Keratinocytes were labeled with BrdU and analyzed by FACS. Data are representative of three individual experiments. Values showing the mean7standard error
of mean are the average of three replicates. Note that upon withdrawal of dox from the medium, fewer keratinocytes incorporated BrdU (high gate R5). (d) Cell
cycle analysis of VP16PPARa BT keratinocytes in the presence or absence of dox by propidium iodide (PI) staining; data are presented from one of three
individual experiments. The group with dox is significantly different from the group without dox. Note that upon withdrawal of dox from the medium, more
kerainocytes were present in the G0/G1 phase. *Significantly different than with dox group (Pp0.05).
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DISCUSSION
This study was designed to determine the role of PPARa
signaling in skin development and physiology and to explore
the potential opportunities for the use of PPARa agonists and
antagonists for the treatment of various skin disorders. To
achieve these goals, transgenic mice were generated by using
the tetracycline regulatory system (Gossen and Bujard, 1992)
to produce a model where PPARa was constitutively
activated in the epidermis and other stratified epithelia
(Diamond et al., 2000). This was achieved by using the
VP16 viral coactivator fused with PPARa to produce a
receptor that is constitutively active in the absence of ligand.
This approach was selected because similar VP16 fusion
proteins have been used to uncover the biological function of
PPARb/d in adipose tissue and PPARg in the mammary gland
(Wang et al., 2003; Saez et al., 2004).
Activation of PPARa in the epidermis led to a phenotype
characterized by thin epidermis and fewer hair follicles in
neonatal mice and by attenuated hyperplasia of interfollicular
epidermis upon topical application of the tumor promotor
TPA in adult mice. While endogenous PPARa was also
induced in this model system, the contribution of this change
to the observed phenotype should not confound the inter-
pretations since both endogenous PPARa and the
VP16PPARa construct should modulate target genes simi-
larly. The induction of the endogenous PPARa gene by the
constitutively activated PPARa is not surprising since earlier
studies in vitro suggested that the human PPARa gene was
autoregulated by PPARa (Pineda Torra et al., 2002).
The epidermis is a tissue with multistratified epithelial
cells, where the keratinocyte is the predominant cell type.
This tissue is continuously renewing and is maintained by a
tightly regulated balance between proliferation, differentia-
tion, and apoptosis. During its maturation in the late stages of
fetal development, the epidermis evolves from a single layer
of epithelial cells to a fully differentiated epithelium. In this
stage, a high level of differentiation is required as keratino-
cytes migrate from the basal to the uppermost layer to form
the stratum corneum (Eckert et al., 1997). The transgenic
mice expressing VP16PPARa exhibit increased keratinocyte
differentiation characterized by altered morphology in
primary keratinocytes and by upregulation of the keratinocyte
differentiation marker genes involucrin and transglutaminase-
1. This is consistent with the reported observation that
activation of PPARa by its ligand induces differentiation in
keratinocytes (Hanley et al., 1998; Komuves et al., 2000a). In
addition, PPARa-null mice show delayed formation of the
stratum corneum during fetal skin development between
embryonic day 18.5 and birth (Schmuth et al., 2002).
Together, these results demonstrate that PPARa activation
regulates differentiation of keratinocytes.
Skin development is also dependent on keratinocyte
proliferation (Eckert et al., 1997). The induction of terminal
differentiation in keratinocytes is associated with a decrease
in cell proliferation (Hennings et al., 1980). This inhibition is
likely the result of signaling to the differentiating keratinocyte
to facilitate the formation of a cornified cell that is relatively
quiescent. However, it is also possible that other signaling
pathways, in addition to those that directly upregulate
proteins required for terminal differentiation, contribute to
the attenuation of cell proliferation. Attenuated keratinocyte
proliferation was demonstrated in primary keratinocytes
expressing the VP16PPARa transgene by reduced cell
numbers, reduced incorporation of BrdU, and increased cells
arresting in the G1 phase. In addition, lower keratinocyte
proliferation was also observed in adult transgenic mice by
attenuated hyperplasia of the interfollicular epidermis upon
topical application of the tumor promotor TPA. These results
are also consistent with the reported observation that PPARa
ligands reduce the proliferation of keratinocytes (Komuves
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Figure 7. Northern blot analysis of differentiation marker and cell cycle regulation gene expression in total keratinocyte RNA from neonatal VP16PPARa BT
mice in the presence (þ ) or absence () of dox and corresponding littermates using probes as indicated. (a) Differentiation markers involucrin and
transglutaminase (Tg-1). (b) Granular layer markers loricrin and filaggrin. (c) Cell cycle regulation genes cyclin D1 and p21. Bar graphs show the relative mRNA
levels regulated by VP16PPARa; the value for each group is the mean7standard error of mean; n¼ 3–4 independent samples per group (*Po0.05).
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et al., 2000a, b). Thus, the decreased proliferation of
keratinocytes might directly cause the observed phenotypes
of thin skin and fewer hair follicles in transgenic neonate
mice. The upregulation of p21 expression in the skin of
transgenic mice expressing VP16PPARa is consistent with the
observed arrest of primary keratinocytes in the G1 phase
because p21 functions to block cell cycle progression in the S
phase, due to its ability to bind to and inhibit proliferating cell
nuclear antigen (Chen et al., 1995). The upregulation of p21
expression is also consistent with the observed decrease of
BrdU incorporation into DNA during the S phase in primary
keratinocytes. Together, these findings suggest that the
upregulation of p21 caused by PPARa signaling is respon-
sible, at least in part, for the decreased proliferation of
keratinocytes from transgenic mice, in addition to the
signaling associated with terminal differentiation. Interest-
ingly, the expression pattern of mouse p21 correlates with
terminal differentiation of multiple tissue types, including
squamous epithelia in a p53-independent manner (Zeng and
el-Deiry, 1996). Thus, the induction of p21 expression by the
expression of VP16PPARa in the skin of transgenic mice may
function as a dual regulator of both cell proliferation and
differentiation. D-type cyclins couple extracellular signals to
the biochemical machinery that governs progression through
the G1 phase (Sherr, 1995). Expression of VP16PPARa caused
decreased cyclin D1 expression and a G1-phase arrest in
keratinocytes. This suggests that cyclin D1 might also play a
role in the regulation of the cell cycle by VP16PPARa.
Presently, no PPARa target genes that directly regulate the
cell cycle have been identified. It is noteworthy that
activation of p21 by overexpression of hepatocyte nuclear
factor-4a in epithelial cells has been shown by others (Chiba
et al., 2005). Since hepatocyte nuclear factor-4a and PPARa
can potentially bind to the same motif composed of a closely
related sequence separated by one nucleotide (direct repeat 1
element) (Hayhurst et al., 2001; Bar-Tana, 2004), their
interaction may influence p21 expression. In addition,
PPARg-dependent activation of p21 was recently observed
in pancreatic cancer cells (Hong et al., 2004). While the
results from these studies indicate that cyclin D1 and p21 can
be regulated by PPARa, it remains unclear whether this is due
to a direct regulation or due to secondary or tertiary PPARa-
dependent events. Thus, whether cyclin D1 or p21 represent
bonafide PPARa target genes requires further examination.
During mouse embryonic development, PPARa has been
detected in the interfollicular epidermis from embryonic day
13.5 onward (Braissant and Wahli, 1998; Michalik et al.,
2001). After birth, PPARa gradually disappears from the
interfollicular epidermis and becomes undetectable in adult
animals (Braissant et al., 1996; Michalik et al., 2001).
Interestingly, under proliferative stimuli such as hair plucking
or wound healing, PPARa is reinduced in the interfollicular
epidermis (Michalik et al., 2001). Results from these studies
demonstrate altered neonatal hair development, which is not
found in adults, and which is consistent with the develop-
mental expression pattern of PPARa. These results indicate
that PPARa signaling is required for the major events of fetal
maturation of the epidermis and homeostasis and functions to
modulate proliferation and differentiation. Interestingly,
although PPARa expression is considerably less than that of
PPARb in response to topical TPA treatment (Michalik et al.,
2001), the observed inhibition of TPA-induced hyperplasia in
the presence of VP16-PPARa expression indicates that
increased expression of PPARa can function to inhibit this
effect. Given the relatively low level of PPARa expression in
skin under these conditions, these results suggest either that
PPARa-dependent induction of differentiation contributes to
the mechanisms underlying this effect or that the constitu-
tively active PPARa could be inducing expression of PPARb
target genes. Indeed, there is good evidence that target genes
containing functional peroxisome proliferator-responsive
elements can be responsive to different PPARs depending
on expression levels. For example, fatty acid transporter is
regulated by PPARa in the liver, but by PPARg in the adipose
tissue, and this is thought to occur because the expression of
PPARa is high in the liver and expression of PPARg is high in
the adipose tissue (Martin et al., 1997; Motojima et al., 1998).
Further, there is evidence that activation of PPARb can inhibit
epithelial cell proliferation by inducing differentiation (Tan
et al., 2001; Westergaard et al., 2001; Schmuth et al., 2004)
and/or by modulating cell proliferation signaling (Kim et al.,
2004, 2005). Combined, these results show that PPARa can
modify the hyperplastic response induced by TPA, and
suggest that this could be due to direct effects mediated by
the VP16-PPARa on putative PPARa target genes and/or
through modulation of PPARb target genes that mediate
similar functional changes.
Another important finding from these studies is the
phenotypic changes observed in several epithelial tissues
targeted by transgene expression (Ramirez et al., 1994). After
birth, the mouse tongue undergoes striking changes to meet
the physiological requirements such as suckling (Henning,
1981). Activation of PPARa in stratified epithelium caused
fewer filiform papillae and more differentiated dorsal lingual
epithelium in the tongue during the late embryonic stage to
birth and impaired suckling. This effect has striking biological
significance and probably directly contributes to the observed
postnatal lethality. It is possible that this defect in tongue
epithelial cell development interferes with food consump-
tion, since crossfostering studies showed that VP16PPARa
transgenic pups fostered on Wt dams still fail to suckle.
However, upon dox treatment of dam mice through the
tetracycline regulatory system (Gossen and Bujard, 1992), the
activated PPARa was diminished and the pups were rescued
from neonatal lethality. Furthermore, reactivating the expres-
sion of PPARa by the withdrawal of dox after birth did not
cause any obvious abnormality in the mice. This indicates
that PPARa signaling has an important role during early
development of the tongue, a developmental window when
high cell proliferation and differentiation is found in this
tissue. Additionally, abnormal development of the mammary
gland was also observed during lactation in the transgenic
mice, which impaired lactation and contributed to early
neonatal mortality. This was demonstrated by the postnatal
lethality observed in Wt pups crossfostered with VP16PPARa
BT mice. Although the exact mechanism(s) of how activation
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of PPARa mediates changes in these epithelial cells remains
unclear, results from the analysis of keratinocytes indicate
that inhibition of proliferation by activation of PPARa could
contribute to these effects. It is also worth noting that
activation of PPARa could lead to changes in the epithelium
in the esophagus that could contribute to the lethal impaired
suckling phenotype. Additionally, it remains a possibility that
accelerated epidermal differentiation due to the activation of
PPARa has a negative effect on perinatal survival.
Based on the known diverse biological activities of PPARa
in epidermal processes such as keratinocyte proliferation and
differentiation, and also attenuating hyperplasia induced by
the tumor promotor TPA, PPARa agonists may be interesting
compounds for the treatment of various epidermal or
epithelial disorders, resulting in the disturbance of normal
tissue homeostasis and epidermal hyperproliferation, such as
skin cancer and psoriasis. In addition, the novel findings of
impaired suckling and lactation by the activation of PPARa
also raise a question about pregnant and lactating women
exposed to PPARa ligands.
MATERIALS AND METHODS
Generation of transgenic mice
The DNA construct used to generate the transgenic mice is shown in
Figure 1a. Mouse PPARa cDNA (Issemann and Green, 1990) was
excised from the parent vector pSG5-PPARa (Akiyama et al., 2002)
with the restriction enzyme BamHI. The termini of this fragment
were filled in with the Klenow fragment of DNA polymerase, and the
blunt-ended fragment was ligated into the pVP16 vector multiple
cloning site (Clontech Laboratories, Palo Alto, CA). The VP16PPARa
sequence was excised from the vector by the restriction enzymes
NheI and DraI digestion, then subcloned into the pTRE vector, which
also contained two direct repeats of insulator sequence. These two
direct repeats of insulator sequence protect transgenes from genomic
position effects, thereby establishing independent functional do-
mains within the chromosome (Chung et al., 1997; Figure 1a). The
orientation and integrity of the cDNA insert was determined by a
series of diagnostic restriction digests and the sequence was verified
using an ABI Prism Big Dye Terminator Kit (Applied Biosystems,
Foster City, CA). The resulting construct contained the TRE promotor
for transcription of the rabbit b-globin and VP16PPARa signal.
The TRE-VP16PPARa transgene was excised from the vector by
restriction enzyme digestion and purified before microinjection into
the nuclei of fertilized FVB/N mouse eggs. The bitransgenic
K5/tTA TREVP16PPARa (designated as VP16PPARa BT) mice were
produced by mating TRE-VP16PPARa transgenic mice to K5/tTA
transgenic mice (FVB/N background, expressing the tTA transgene
under the control of bovine keratin 5 promoter (Diamond et al.,
2000).
The transgenic animals were screened by Southern blot analysis
or PCR of tail DNA. The primers for the TRE-VP16PPARa were: 50-
GCTCGTTTAGTGAACCGTC (forward) and 50-GGTAAACATCTGC
TCAAACTCG (reverse), which yielded a 400-bp fragment. The
primers for the tTA and mouse endogenous PPARa were described
previously (Diamond et al., 2000; Cheung et al., 2004).
Mice were maintained under a standard 12-hours light/12-hours
dark cycle with water and chow provided ad libitum. Animal
handling was in accordance with animal study protocols approved
by the National Cancer Institute Animal Care and Use Committee.
Some mice were administered dox (200 mg/kg; Bio-Serv, French-
town, NJ) in the diet to regulate the expression of PPARa. The
expression and regulation of the VP16PPARa transgene was
analyzed by Northern and Western blot analysis.
Transient transfection luciferase assay
NIH-3T3 cells were cultured in DMEM containing 10% fetal bovine
serum and 100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad,
CA). The cells were seeded in 24-well tissue culture plates, grown to
90–95% confluency, and transfected with 200 ng peroxisome
proliferator-responsive element3-TK-Luc, 100 ng pSG5-retinoid X
receptor, 200 ng pUC19, and 200 ng of one of the following
plasmids: pUC19, pSG5-PPARa, pVP16PPARa, and pTRE-
VP16PPARa using LipofectAMINE 2000 (Invitrogen) (Akiyama
et al., 2002). As an internal control, the plasmid pRL-TK containing
the Renilla luciferase gene was cotransfected. To compare the effect
of PPARa ligand with constitutively activated PPARa or dox
regulation, after incubation for 24 hours at 371C, Wy-14,643 or
dox was added to the culture medium and further incubated at 371C
for 24 hours before the cells were lysed with a passive lysis buffer
(Promega). Luciferase activity was measured using the manufac-
turer’s recommended protocol for the Dual-Luciferase Reporter
Assay System (Promega).
Northern blot analysis
Northern blot analysis was carried out as described previously
(Akiyama et al., 2000). Total RNA was extracted from the skin or
other tissues using TRIzol reagent (Invitrogen) following the
manufacturer’s protocol. Total RNA was resuspended in diethylpyro-
carbonate-treated water and quantified by spectrophotometry and
10 mg of total RNA was electrophoresed on a 1.0% agarose gel
containing 0.22 M formaldehyde, transferred to a nylon membrane,
and crosslinked by UV light exposure. The following previously
described cDNA probes were used for Northern blotting: PPARa
adipose differentiation-related protein, fasting-induced adipose
factor, cyclin D1, p21, involucrin, transglutaminase-1, loricrin,
filaggrin, and 18S as a loading control (Lee et al., 1995, 1998; Peters
et al., 2000; Tremain et al., 2000; Matsusue et al., 2004; Schmuth
et al., 2004). Membranes were hybridized in ULTRAhyb buffer
(Ambion, Austin, TX) with random primer 32P-labeled cDNA probes
(Lee et al., 1995; Akiyama et al., 2000) following the manufacturer’s
protocol, and washed with salt/detergent solution using standard
procedures.
Immunoblot analysis
Immunoblot analysis of VP16PPARa was carried out with keratino-
cyte lysates and using rabbit anti-PPARa (Santa Cruz Biotechnology
Inc., Santa Cruz, CA), anti-rabbit IgG horseradish peroxidase
secondary antibodies (Sigma), and an enhanced chemiluminescence
detection kit (Pierce). Goat anti-b-actin (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) was used as a loading control.
Hyperproliferative skin by TPA
To determine the effect of the VP16PPARa transgene in a
hyperplastic skin model, adult mice (8–10 weeks of age) from both
genotypes were shaved of dorsal hair, and 24 hours later, treated
topically with either acetone or 5 mg of TPA dissolved in 200 ml of
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acetone as described (Peters et al., 2000). Skin samples were
collected 48 hours post-TPA.
Histological analyses
Mice were killed by overexposure to carbon dioxide. The dorsal
skin and internal organs were excised, fixed in 10% neutral-
buffered formalin (Fisher Scientific, Fair Lawn, NJ), embedded in
paraffin, and 4- to 6-mm sections were prepared. Sections were
stained with hematoxylin and eosin, and were evaluated by light
microscopy.
Analysis of postnatal development
Breeding pairs of indicated mice were bred and examined for the
presence of copulatory plug (gestation day 0). Upon delivery of
offspring (gestation day 19), the number of pups was noted and the
litters were examined every 24 hours.
To determine the effects of the VP16PPARa transgene on pups,
transgenic TRE-VP16PPARa mice were bred with transgenic K5/tTA
mice. A total of 95 pups from both genotypes (Wt, TRE-VP16PPARa,
K5/tTA, and K5/tTA TREVP16PPARa) were examined, with an
average litter size of 771 pups. A separate cohort of mice was used
to examine the effects of feeding dox, where a total of 36 litters, with
an average litter size of 771, were examined from each genotype.
To determine the effects of the VP16PPARa transgene on the
mammary gland, heterozygous VP16PPARa BT mice were bred.
A total of 57 pups derived from eight litters and having both
genotypes (Wt, TRE-VP16PPARa, K5/tTA, and VP16PPARa BT) were
examined, with an average litter size of 771 pups. A separate cohort
of mice was used to examine the effects of feeding dox, where a total
of 99 litters, with an average litter size of 771, were examined from
each genotype.
For crossfostering experiments, breeding pairs of either homo-
zygous Wt or VP16PPARa BT mice were bred and upon delivery of
offspring, Wt pups were crossfostered with VP16PPARa BT dams, or
VP16PPARa BT pups were crossfostered with Wt dams. A total of 53
litters from each genotype with an average litter size of 771 pups
were examined.
Mammary gland whole mounts
The preparation of mammary glands has been described previously
(http://mammary.nih.gov/methodcd/methodcd.html). Briefly, ab-
dominal mammary glands were collected on parturition day 1.
One gland from each animal was mounted onto a glass slide under
weight, and fixed in Carnoy’s fixative (6:3:1 ethanol:chloroform:
glacial acetic acid). Fixed glands were transferred to 70% ethanol
with gradual dilution to water. They were then stained with carmine
alum. After rinsing in water, and gradually dehydrating to 100%
ethanol, the glands were cleared with xylene and mounted on slides
using Permount (Fisher Scientific, Pittsburgh, PA).
Keratinocyte culture
A previously described method (Dlugosz et al., 1995) was used to
culture keratinocytes obtained from 1-day-old neonates from Wt,
TREVP16PPARa, K5/tTA, or VP16PPARa BT mice. Briefly, keratino-
cytes from the same genotype were pooled and equivalent numbers
(2 105) of keratinocytes were seeded into a 12-well culture dish
and cultured in low-calcium medium (0.05 mM) containing 2 ng/ml
of dox. After 24 hours of culture, the medium was changed to low
calcium with or without dox for the remainder of the culture period.
The RNA was isolated from cells using TRIzol reagent as described
above.
BrdU labeling of keratinocyte and FACS analysis
Cellular proliferation was assessed by DNA content and incorpora-
tion of BrdU by multiparameter flow cytometry as described
previously (Glick et al., 1999). Briefly, after 48 hours of culture in
low-calcium medium with or without dox, subconfluent cells were
pulsed with BrdU (10 mM; Sigma) for 2 hours, rinsed with phosphate-
buffered saline (PBS), trypsinized, isolated by centrifugation, washed
in PBS, and fixed in 70% ethanol for at least 1 hour at 201C. Cells
were then centrifuged at 2,000 r.p.m., resuspended in 1 ml of 0.2 mg/ml
pepsin (Sigma) in 2 N HCl, and incubated for 30 minutes at room
temperature. After neutralization of the samples by addition of 3 ml
of 0.1 M Na2B4O7, cells were washed with PBS supplemented with
0.5% Tween 20 and 2% fetal calf serum. After centrifugation, the
cells were resuspended in 100ml of the above PBS containing 5 ml of
FITC-conjugated anti-BrdU antibody (Alexis Corporation) and
stained for 30 minutes at room temperature. After two washes with
PBS, cells were incubated in 500 ml PBS containing 0.5 mg/ml
RNAase A and 50 mg/ml propidium iodide (Sigma) for at least
30 minutes at room temperature. Samples were then analyzed for
DNA content using a FACScalibur flow cytometer (Becton Dickin-
son). The percentage of cells incorporating BrdU during the 2 hours
pulse was estimated from simultaneous staining with FITC-con-
jugated antibody (FL1 channel) and the log red fluorescence
detected on the FL-2 channel, using CellQuest sofware. The
percentage of cells in each phase of the cell cycle was estimated
using the MODFIT program.
Data analysis
All data are presented as the mean7standard error of mean. The
differences between groups were assessed by analysis of variance.
Differences were considered statistically significant at Po0.05.
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